Literature DB >> 25759241

Drug-induced EEG pattern predicts effectiveness of ketamine in treating refractory status epilepticus.

Maysaa M Basha1, Abdulradha Alqallaf, Aashit K Shah.   

Abstract

Refractory status epilepticus (RSE) can lack overt clinical manifestation and is usually treated with continuous infusion of intravenous anesthetic drugs (IVADs), where the use of continuous electroencephalography (cEEG) is imperative. Ketamine has recently been shown to be effective in the treatment of RSE. We retrospectively review a cohort of 11 patients receiving ketamine as part of their treatment regimen for RSE. We report on the presence of a characteristic EEG rhythm consisting of a generalized archiform theta to beta rhythms (7-20 Hz) appearing after ketamine administration. This pattern was seen in five patients, four of whom achieved successful resolution of RSE. Ketamine-induced EEG pattern may serve as a biomarker predictive of successful treatment outcome in RSE. Wiley Periodicals, Inc.
© 2015 International League Against Epilepsy.

Entities:  

Keywords:  Continuous EEG; Intravenous anesthetic drugs; Status epilepticus treatment

Mesh:

Substances:

Year:  2015        PMID: 25759241     DOI: 10.1111/epi.12947

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  10 in total

1.  Ketamine for Refractory Status Epilepticus: A Systematic Review.

Authors:  Anna Rosati; Salvatore De Masi; Renzo Guerrini
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

2.  Enhanced AMPA receptor-mediated neurotransmission on CA1 pyramidal neurons during status epilepticus.

Authors:  Suchitra Joshi; Karthik Rajasekaran; Huayu Sun; John Williamson; Jaideep Kapur
Journal:  Neurobiol Dis       Date:  2017-04-02       Impact factor: 5.996

3.  Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee.

Authors:  David G Vossler; Jacquelyn L Bainbridge; Jane G Boggs; Edward J Novotny; Tobias Loddenkemper; Edward Faught; Marta Amengual-Gual; Sarah N Fischer; David S Gloss; Donald M Olson; Alan R Towne; Dean Naritoku; Timothy E Welty
Journal:  Epilepsy Curr       Date:  2020-08-21       Impact factor: 7.500

4.  Electrographic predictors of successful weaning from anaesthetics in refractory status epilepticus.

Authors:  Daniel B Rubin; Brigid Angelini; Maryum Shoukat; Catherine J Chu; Sahar F Zafar; M Brandon Westover; Sydney S Cash; Eric S Rosenthal
Journal:  Brain       Date:  2020-04-01       Impact factor: 15.255

Review 5.  Updates in Refractory Status Epilepticus.

Authors:  Rohit Marawar; Maysaa Basha; Advait Mahulikar; Aaron Desai; Kushak Suchdev; Aashit Shah
Journal:  Crit Care Res Pract       Date:  2018-05-08

6.  Refractory Status Epilepticus Responsive to Electroacupuncture at Shuigou Acupoint: A Case Report.

Authors:  Fang Yuan; Aili Lu; Shibiao Wu; Lixin Wang
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

Review 7.  Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus.

Authors:  Michael E Reznik; Karen Berger; Jan Claassen
Journal:  J Clin Med       Date:  2016-05-19       Impact factor: 4.241

8.  (S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study.

Authors:  Julia Höfler; Alexandra Rohracher; Gudrun Kalss; Georg Zimmermann; Judith Dobesberger; Georg Pilz; Markus Leitinger; Giorgi Kuchukhidze; Kevin Butz; Alexandra Taylor; Helmut Novak; Eugen Trinka
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

9.  New-Onset Refractory Status Epilepticus: More Investigations, More Questions.

Authors:  Philippe Dillien; Susana Ferrao Santos; Vincent van Pesch; Vanessa Suin; Sophie Lamoral; Philippe Hantson
Journal:  Case Rep Neurol       Date:  2016-06-14

10.  Ketamine in adult super-refractory status epilepticus: Efficacy analysis on a prospective registry.

Authors:  Leonardo Caranzano; Jan Novy; Andrea O Rossetti
Journal:  Acta Neurol Scand       Date:  2022-03-11       Impact factor: 3.915

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.